Cellectar Biosciences (CLRB) vs Tempest Therapeutics (TPST)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Cellectar Biosciences (CLRB) has outperformed Tempest Therapeutics (TPST) over the past year, losing 70.6% versus a loss of 92.6%. Over five years, CLRB leads with a -99.5% price change compared with -99.6% for TPST. Cellectar Biosciences is the larger company by market cap ($13.5 million vs $13.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CLRB | TPST |
|---|---|---|
| Share price | $1.43 | $0.7873 |
| Market cap | $13.52M | $13.30M |
| 1-day change | -5.30% | -0.52% |
| YTD return | -48.81% | -72.43% |
| 1-year return | -70.57% | -92.63% |
| 5-year return | -99.45% | -99.59% |
| EPS (TTM) | $-3.46 | $-3.93 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.07 | $12.23 |
| 52-week low | $1.42 | $0.743 |
| Distance from 52-week high | -71.79% | -93.56% |
| Average volume | 61.52K | 2.59M |
| Shares outstanding | 9.45M | 16.89M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CLRB has outperformed TPST by 22.1 percentage points over the past year.
CLRB vs TPST FAQ
Which is bigger, Cellectar Biosciences or Tempest Therapeutics?
Cellectar Biosciences (CLRB) is larger, with a market capitalization of $13.52M compared with $13.30M for Tempest Therapeutics (TPST).
Which stock has performed better over the past year, CLRB or TPST?
CLRB returned -70.57% over the past 12 months, compared with -92.63% for TPST (price return, excluding dividends). Past performance does not predict future results.
Are Cellectar Biosciences and Tempest Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.